Pharma shares witnessed buying demand for second consecutive trading session.
At 14:25 IST, the barometer index, the S&P BSE Sensex surged 569.20 points or 0.67% to 85,498.66. The Nifty 50 index added 186.75 points or 0.72% to 26,151.26.
The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.84% and the S&P BSE Small-Cap index added 1.16%.
The market breadth was weak. On the BSE, 2,789 shares rose and 1,449 shares fell. A total of 214 shares were unchanged.
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, jumped 1.86% to 9.70.
India-New Zealand Agreement:
India and New Zealand concluded a comprehensive, balanced and forward-looking Free Trade Agreement (FTA) under the visionary leadership of Honble Prime Minister Shri Narendra Modi, marking a major economic and strategic milestone in Indias engagement with the Indo-Pacific region.
India has secured commitments across a wide range of high-value sectors including IT and IT-enabled services, professional services, education, financial services, tourism, construction and other business services, opening substantial new opportunities for Indian service suppliers and high-skill employment.
New Zealand has committed to facilitate investments of USD 20 billion into India over the next fifteen years, thereby supporting manufacturing, infrastructure, services, innovation and employment under Indias Make in India vision. Indian enterprises are also expected to benefit from their presence in New Zealand and access the wider Pacific Island markets.
Buzzing Index:
The Nifty Pharma index advanced 0.72% to 22,915.05 The Index rose 1.58% for the two consecutive trading sessions.
Piramal Pharma (up 3.99%), Wockhardt (up 2.65%), Ajanta Pharma (up 2.56%), Glenmark Pharmaceuticals (up 2.36%) and Laurus Labs (up 2.33%), Ipca Laboratories (up 1.43%), Alkem Laboratories (up 1.38%), Sun Pharmaceutical Industries (up 1.05%), Gland Pharma (up 0.88%) and Divis Laboratories (up 0.64%) surged.
Numbers to Track:
The yield on India's 10-year benchmark federal paper rose 0.67% to 6.650 compared with previous session close of 6.606.
In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 89.5900 compared with its close of 89.6700 during the previous trading session.
MCX Gold futures for 5 February 2026 settlement advanced 1.26% to Rs 135,888.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.10% to 98.50.
The United States 10-year bond yield declined 0.43% to 4.163.
In the commodities market, Brent crude for February 2025 settlement jumped 57 cents or 0.57% to $61.04 a barrel.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
